SPHINX31 acts as a SRPK1 inhibitor targeting the ATR / DNA ‐ PKcs / CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer
Open Access
- 17 September 2026
- journal article
- Published by Wiley in Molecular Oncology
Abstract
Splicing targeting drugs have emerged as promising anticancer drugs. However, their mechanisms of action remain largely unknown, notably in Non‐Small Cell Lung Carcinoma (NSCLC). In this study, we demonstrated that SPHINX31, which targets SRPK1, inhibits the ATR/CHK1 signaling pathway, a cornerstone of the replicative stress response, leading to decreased cell proliferation, increased DNA damage and apoptosis, notably in NSCLC cells resistant to platinum salts. Mechanistically, we found that SRPK1 is recruited at stalled replication forks upon replicative stress, co‐immunoprecipitates with the ATR/ATRIP/TOPBP1 complex, directly interacts with TOPBP1 BRCT4/5 and BRCT7/8 domains, and contributes to the accumulation of TOPBP1 nuclear foci. We further showed that SRPK1 controls the splicing of genes previously related to ATR signaling, notably WIZ . All these events are prevented by SPHINX31. Lastly, we showed that the inhibitory effects of SPHINX31 on ATR are counterbalanced by the activation of DNA‐PKcs. Altogether, this study uncovers SRPK1 as a new component of the ATR/DNA‐PKcs/CHK1 replicative checkpoint. SRPK1 inhibitors, alone or in combination with DNA‐PKcs or CHK1 inhibitors, could provide therapeutic benefit in NSCLC patients including those who relapse after platinum‐based chemotherapy.Keywords
Funding Information
- Fondation du Souffle (Appel à Projet Formation Pour La Recherche 2023 P)
- Centre National de la Recherche Scientifique
- Ligue Contre le Cancer (Comité Allier)
- Ligue Contre le Cancer (Comité Savoie)
- Ligue Contre le Cancer (comité Isère)
- Institut National de la Santé et de la Recherche Médicale
- Communauté Université Grenoble Alpes
- Ministère de l'Enseignement supérieur et de la Recherche (Allocation Doctorale)
- Institut National Du Cancer (PLBIO2020‐115)
- Institut National Du Cancer (PLBIO2022‐188)
- Agence Nationale de la Recherche (AAPG‐2023)
- French Infrastructure for Integrated Structural Biology
- Groupement des Entreprises Françaises dans la lutte contre le Cancer
This publication has 102 references indexed in Scilit:
- PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitaxel in non-resectable or metastatic pancreatic cancerInvestigational New Drugs, 2025
- Serine-arginine protein kinases and their targets in viral infection and their inhibitionCellular and Molecular Life Sciences, 2023
- Serine-Arginine Protein Kinase 1 (SRPK1): a systematic review of its multimodal role in oncogenesisMolecular and Cellular Biochemistry, 2022
- Targeting the spliceosome machinery: A new therapeutic axis in cancer?Biochemical Pharmacology, 2021
- Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung CancerJAMA, 2019
- Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 PatientsCancer Cell, 2018
- Modulating splicing with small molecular inhibitors of the spliceosomeWIREs RNA, 2016
- Purification of Proteins on Newly Synthesized DNA Using iPOND2014
- Phosphorylation of the arginine/serine repeats of lamin B receptor by SRPK1—Insights from molecular dynamics simulationsBiochimica et Biophysica Acta (BBA) - General Subjects, 2012
- SRPK1: A cisplatin sensitive protein expressed in retinoblastomaPediatric Blood & Cancer, 2006